An observational study in Obesity, Childhood, Hyperphagia and Retinopathy, sponsored by Rolfs Consulting und Verwaltungs-GmbH (RCV). Active, not recruiting at 37 sites in Germany. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Rolfs Consulting und Verwaltungs-GmbH (RCV) · Observational
TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO)
DESIGN: Multicenter epidemiological study
STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)
NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation
COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs
TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO)
DESIGN: Multicenter epidemiological study
STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)
NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation
COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs
PARTICIPATING COUNTRY: Germany
TREATMENT: Not applicable
PRIMARY OBJECTIVE: To investigate the prevalence of BBS in an at-risk population
SECONDARY OBJECTIVES:
DURATION OF RECRUITMENT: 32 months - total
24 months the recruitment of 1000 subjects
27 months follow up visits
32 months close out of sites
INCLUSION CRITERIA:
For a participant between 2 and 18 years of age:
rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism
For a participant who is 18 years of age or older:
1,129 studies on the registry are indexed under Pediatric Obesity; 187 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 180 across 235 observational studies indexed under Pediatric Obesity.
Browse Pediatric Obesity studies →This is the only study on the registry with Rolfs Consulting und Verwaltungs-GmbH (RCV) as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For a participant between 2 and 18 years of age:
rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism
For a participant who is 18 years of age or older:
Exclusion criteria:
- Not fulfilling the inclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants suspected to genetic obesity
Diagnostic Test: Genetic testing via blood collection
blood collection
BBS prevalence
To investigate the prevalence of BBS in patients suspected to a genetic obesity
Time frame: 2 years
Phenotypic and genetic characterization
To understand the genotype-phenotype correlation; to assess genotypes distribution in Germany and compare to other countries; to identify new genes/variants; to investigate clinical characteristics in individuals diagnosed with BBS
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.
Of 94 non-industry observational studies under Pediatric Obesity, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 132. This study's planned 25 months is below that.
Counting every sponsor, half of 96 studies reached it within 52 months; a quarter within 21 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.